Abstract 2554
Background
The IDEA study showed that the type and duration of adjuvant chemotherapy in stage III colon cancer (CC) could be adjusted according to level of risk (Grothey et al., New Engl J Med 2018). One year after the publication of IDEA study, we performed an audit of real-life practices in France.
Methods
We conducted an online anonymized nationwide survey from January 30, 2019 to March 31, 2019. An invitation email followed by reminders every 2 weeks was sent to clinicians using the oncology cooperative groups GERCOR, FFCD and GI UNICANCER mailing lists. All of the answers were declarative, individual, and anonymized. Proportions were compared using chi-squared test.
Results
A total of 213 physicians answered the survey: 31% worked in an academic hospital, 27% in a general hospital, 26% in a comprehensive cancer center and 16% in a private clinic. Main responders were gastroenterologists (51%) or medical oncologists (39%). 47% of physicians took care of more than 12 stage III CC patients per year. For low risk stage III CC (T1-T3 and N1), 81% preferred a 3-month duration of treatment, and 74% used capecitabine plus oxaliplatine (CAPOX) as the standard regimen. 66% of CAPOX for 3 months were realized without central venous access device, which was necessary during treatment in less than 25% of cases according to 68% of the responders. Physicians choosing 6-month duration of adjuvant treatment for low risk stage III CC were more often medical oncologists (58% versus 35%, P = 0.009) or working in a general hospital (48% versus 22%, P = 0.001); no significant difference was observed considering years of professional experience or the number of patients treated per year. For high risk stage III CC (T4 and/or N2), 99.5% of responders considered that adjuvant chemotherapy should be prescribed for 6 months, and 94% with FOLFOX.
Conclusions
One year after the publication of the IDEA study, 3 months of adjuvant chemotherapy with CAPOX has been mainly integrated as a new standard of care for low risk stage III CC patients in daily practice whereas 6 months of FOLFOX remains the standard of care of high risk stage III CC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
GERCOR.
Funding
Has not received any funding.
Disclosure
B. Rousseau: Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Research grant / Funding (institution), Travel / Accommodation / Expenses: Servier; Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Research grant / Funding (institution), Travel / Accommodation / Expenses: Gilead; Research grant / Funding (institution), Travel / Accommodation / Expenses: AbbVie. All other authors have declared no conflicts of interest.
Resources from the same session
3911 - Defining a SUV decrease cut-off in PET/CT response monitoring after one cycle of preoperative breast cancer chemotherapy
Presenter: Marcin Kubeczko
Session: Poster Display session 2
Resources:
Abstract
1849 - Effect of thioredoxin 1 quantity detection to complement the mammography in breast cancer diagnosis
Presenter: Younju Lee
Session: Poster Display session 2
Resources:
Abstract
2221 - Identification of ultralow risk breast cancer patients (probable overdiagnosis)
Presenter: Salvador Gamez Casado
Session: Poster Display session 2
Resources:
Abstract
5291 - Prevalence of Vitamin D3 deficiency among women with early breast cancer receiving chemotherapy in an oncology dayward.
Presenter: Warner Finstad
Session: Poster Display session 2
Resources:
Abstract
4247 - Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients
Presenter: Arran Turnbull
Session: Poster Display session 2
Resources:
Abstract
568 - Second primary malignancies in patients with breast cancer.
Presenter: Carlos Erasun Lecuona
Session: Poster Display session 2
Resources:
Abstract
1428 - Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) Breast Cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
Presenter: Laura Biganzoli
Session: Poster Display session 2
Resources:
Abstract
1479 - Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): an open label randomized phase 2 trial
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
1481 - A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
4334 - ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer.
Presenter: Michail Ignatiadis
Session: Poster Display session 2
Resources:
Abstract